Relapse Duration, Treatment Intensity, and Brain Tissue Loss in Schizophrenia: A Prospective Longitudinal MRI Study
TLDR
Extended periods of relapse may have a negative effect on brain integrity in schizophrenia, suggesting the importance of implementing proactive measures that may prevent relapse and improve treatment adherence.Abstract:
ObjectiveLongitudinal structural MRI studies have shown that patients with schizophrenia have progressive brain tissue loss after onset. Recurrent relapses are believed to play a role in this loss, but the relationship between relapse and structural MRI measures has not been rigorously assessed. The authors analyzed longitudinal data to examine this question.MethodsThe authors studied data from 202 patients drawn from the Iowa Longitudinal Study of first-episode schizophrenia for whom adequate structural MRI data were available (N=659 scans) from scans obtained at regular intervals over an average of 7 years. Because clinical follow-up data were obtained at 6-month intervals, the authors were able to compute measures of relapse number and duration and relate them to structural MRI measures. Because higher treatment intensity has been associated with smaller brain tissue volumes, the authors also examined this countereffect in terms of dose-years.ResultsRelapse duration was related to significant decreases...read more
Citations
More filters
Journal ArticleDOI
Improving outcomes of first-episode psychosis: an overview
TL;DR: To improve outcomes of a complex, heterogeneous syndrome such as psychosis, it is necessary to globally adopt complex models integrating a clinical staging framework and coordinated specialty care programmes that offer pre‐emptive interventions to high‐risk groups identified across the early stages of the disorder.
Journal ArticleDOI
Accelerated brain aging in schizophrenia : A longitudinal pattern recognition study
Hugo G. Schnack,Neeltje E.M. van Haren,Mireille Nieuwenhuis,Hilleke E. Hulshoff Pol,Wiepke Cahn,René S. Kahn +5 more
TL;DR: The progressive brain loss in schizophrenia appears to reflect two different processes: one relatively homogeneous, reflecting accelerated aging of the brain and related to various measures of outcome, and a more variable one, possibly reflecting individual variation and medication use.
Journal ArticleDOI
Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis
TL;DR: Physical exercise is a robust add-on treatment for improving clinical symptoms, quality of life, global functioning, and depressive symptoms in patients with schizophrenia and yoga improved the cognitive subdomain long-term memory while exercise in general or in any other form had no effect on cognition.
Journal ArticleDOI
Biomarkers and clinical staging in psychiatry.
Patrick D. McGorry,Matcheri S. Keshavan,Sherilyn Goldstone,Paul Amminger,Kelly Allott,Michael Berk,Suzie Lavoie,Christos Pantelis,Alison R. Yung,Stephen J. Wood,Ian B. Hickie +10 more
TL;DR: The staging model explicitly considers the evolution of psychopathology during the development of a mental illness and emphasizes that progression of illness is by no means inevitable, but can be altered by providing appropriate interventions that target individual modifiable risk and protective factors.
Journal ArticleDOI
The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies.
TL;DR: Findings in this study add useful information to the controversial debate on the brain structural effects of antipsychotic medication and may have both clinical relevance and theoretical implications.
References
More filters
Book
The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020.
TL;DR: This is the first in a planned series of 10 volumes that will attempt to "summarize epidemiological knowledge about all major conditions and most risk factors" and use historical trends in main determinants to project mortality and disease burden forward to 2020.
Journal ArticleDOI
Implications of normal brain development for the pathogenesis of schizophrenia
TL;DR: The findings suggest that nonspecific histopathology exists in the limbic system, diencephalon, and prefrontal cortex, that the pathology occurs early in development, and that the causative process is inactive long before the diagnosis is made.
Journal ArticleDOI
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Nancy C. Andreasen,William T. Carpenter,John M. Kane,Robert A. Lasser,Stephen R. Marder,Daniel R. Weinberger +5 more
TL;DR: The first consensus-based operational criteria for symptomatic remission in schizophrenia are based on distinct thresholds for reaching and maintaining improvement, as opposed to change criteria, allowing for alignment with traditional concepts of remission in both psychiatric and nonpsychiatric illness.
Journal ArticleDOI
The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.
TL;DR: Research strategies suggest that investigators should maintain a flexible database to permit them to adapt to changes in diagnostic systems, to do comparative nosological studies, and, ultimately, to develop new diagnostic systems based on knowledge concerning the underlying neurobiological nature of disorders.